Hyporesponse to anemia drugs leads to higher risk of hospitalizations, death

AUSTIN, Texas —Patients on dialysis who are hyporesponsive to anemia treatment have a higher risk for hospitalizations and death, according to data presented here.
“Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events,” Christine Ferro, BA, and colleagues wrote in a poster presented at the National Kidney Foundation Spring Clinical Meetings. “We compared rates of acute inpatient (AIP) admission, 30-day readmission, and mortality between Medicare patients with and without hypoR to ESAs.”
Patients in the study were on

AUSTIN, Texas —Patients on dialysis who are hyporesponsive to anemia treatment have a higher risk for hospitalizations and death, according to data presented here.
“Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events,” Christine Ferro, BA, and colleagues wrote in a poster presented at the National Kidney Foundation Spring Clinical Meetings. “We compared rates of acute inpatient (AIP) admission, 30-day readmission, and mortality between Medicare patients with and without hypoR to ESAs.”
Patients in the study were on